[caption id="attachment_72368" align="aligncenter" width="500"]
Freepix[/caption]
The unmet need of Parkinson’s disease
Parkinson's disease (PD) is a progressive neurodegenerative disease of the central nervous system (CNS). The condition causes neurons in parts of the brain to become weak, damaged, and die, leading to symptoms of muscle stiffness, resting tremors, impaired balance, and problems with movement and expression. In addition to the obvious physical symptoms, people suffering from Parkinson’s disease often face mental and emotional health problems, difficulty swallowing and chewing, changes to their speech, skin, and sleep, as well as pain and fatigue, muscle cramps, and a whole range of potential cognitive and psychiatric issues. According to the
World Health Organization, Parkinson’s disease is the world’s fastest growing neurological disorder, with prevalence having doubled in the last 25 years, accounting for almost 8.5 million cases globally.
Current treatment options focus on symptom management, including dopaminergic therapies and enzyme inhibitors, with no cure and no currently available treatments to stop disease progression. Parkinson’s disease, therefore, remains a significant research priority, with the focus currently placed on finding treatments that can effectively slow disease progression, while continuing to enhance existing symptomatic treatments. Research in this area is complex, given the heterogeneity of symptoms, gradual neurodegeneration, and subtle early disease changes, the combination of which makes clinical trial imaging particularly challenging. This article will consider the current landscape of PD-specific imaging modalities and their applications, as well as highlighting the role of an
experienced imaging clinical research organization (CRO) in CNS clinical trials management.